off-the-shelf– tag –
-
Lineage Cell Therapeutics Continues Support for Roche/Genentech’s OpRegen Cell Therapy, AlloSCOPE™ Platform Enables Scalable Manufacturing
Business Wire USA Overview Lineage Cell Therapeutics reported Q2 2026 financial results and business updates, confirming continued support for its OpRegen cell therapy development collaboration with Roche and Genentech, including technic... -
Cell Therapy Clinical Success Hinges on Manufacturability: Limitations of Autologous Therapies Drive Interest in Allogeneic ‘Off-the-Shelf’ Platforms
Cell & Gene Unknown Overview Cell therapy scalability is a critical factor to consider from early development, as autologous therapies face challenges in manufacturing complexity, scheduling constraints, and inherent scalability limitati... -
Fate Therapeutics Executives Sell Shares Post-FDA IND Approval for Next-Gen Autoimmune CAR-T Candidate FT839, Market Anticipates Basket Trial Success
TipRanks USA Overview Fate Therapeutics executives engaged in significant insider stock sales following news of the U.S. FDA's Investigational New Drug (IND) approval for FT839, its next-generation off-the-shelf CAR-T candidate for autoi... -
EUDA Health Partners with GO POSB and SIIT to Accelerate Off-the-Shelf iPSC Cell Therapy for Oncology and Wellness
Stock Titan Singapore Overview EUDA Health announced a collaboration to integrate GO POSB's iPSC platform with SIIT's NK and NK-TCR cell engineering capabilities, aiming to advance off-the-shelf cell therapy programs in oncology and well... -
Allogeneic CAR T-Cells: The Off-the-Shelf Revolution in Cancer Immunotherapy Manufacturing
Liv Hospital Turkey Overview Autologous CAR T-cell therapies face significant hurdles in scalability and turnaround time, limiting their broad accessibility. The industry is rapidly shifting towards off-the-shelf allogeneic CAR T-cells, ... -
XellSmart Secures FDA Fast Track Designation for Off-the-Shelf iPSC-Derived Cell Therapy XS411 for Parkinson’s Disease
BioSpace (XellSmart) USA Overview XellSmart announced that its allogeneic, off-the-shelf iPSC-derived cell therapy candidate, XS411, for Parkinson's disease has received Fast Track Designation (FTD) from the U.S. FDA. XS411 aims to repla... -
Washington University-Developed CAR-T Therapy for T-Cell Leukemia and Lymphoma Receives FDA Breakthrough Therapy Designation: Off-the-Shelf Approach Improves Access
Washington University School of Medicine in St. Louis USA Overview A cell-based immunotherapy developed by Washington University School of Medicine in St. Louis, designed to treat rare and aggressive T-cell acute lymphoblastic leukemia a... -
Automated GMP Facility Launched, Supercharging Scalable Production for Off-the-Shelf Cell Therapies
Company Announcement / Specialized Media International Overview A new, state-of-the-art GMP facility dedicated to commercial-scale allogeneic cell therapy manufacturing has commenced operations. This facility leverages advanced automatio... -
BioInformant Details 2026 iPSC-Derived Cell Therapeutics Pipeline: Key Players Accelerate Clinical Development for Parkinson’s, Heart Failure, Cancer, and More
BioInformant USA Overview BioInformant's comprehensive report outlines the 2026 pipeline for iPSC-derived cell therapeutics, highlighting progress from key companies like Fate Therapeutics, BlueRock Therapeutics, FUJIFILM Cellular Dynami... -
Century Therapeutics Pivots iPSC Platform to Type 1 Diabetes Beta Cell Therapy, Targeting 2025 IND with Off-the-Shelf Approach
Century Therapeutics USA Overview Century Therapeutics has announced a strategic realignment of its induced pluripotent stem cell (iPSC) platform, now exclusively dedicated to developing beta islet cell therapy for Type 1 Diabetes. The c...
